Protein arginine methyltransferase 2 (PRMT2) promotes dextran sulfate sodium‐induced colitis by inhibiting the SOCS3 promoter via histone H3R8 asymmetric dimethylation
- 2 October 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (1) , 141-158
Abstract
Background and Purpose: There is emerging evidence for a critical role for epigenetic modifiers in the development of inflammatory bowel disease (IBD). Protein arginine methyltransferase 2 (PRMT2) is responsible for the methylation of arginine residues on histones and targets transcription factors involved in many cellular processes, including gene transcription, mRNA splicing, cell proliferation, and cell differentiation. In this study, the role and underlying mechanisms of PRMT2 in colitis were studied.Experimental Approach: A mouse dextran sulfate sodium (DSS)‐induced experimental colitis model was used to study PRMT2 in colitis. Lentivirus‐induced PRMT2 silencing or overexpression in vivo was applied to address the role of PRMT2 in colitis. Detailed western blot and expression analysis were done to understand epigenetic changes induced by PRMT2 in colitis.Key Results: PRMT2 is highly expressed in inflammatory bowel disease patients, in inflamed murine colon and in TNF‐α stimulated murine gut epithelial cells. PRMT2 overexpression aggravates, while knockdown alleviates DSS‐induced colitis, suggesting that PRMT2 is a pivotal mediator of colitis in mice. Mechanistically, PRMT2 mediates colitis by increasing repressive histone mark H3R8 asymmetric methylation (H3R8me2a) at the promoter region of the suppressor of cytokine signalling 3 promoter (SOCS3). Resultant inhibition of SOCS3 expression and inhibition of SOCS3‐mediated degradation of TNF receptor associated factor 5 (TRAF5) via ubiquitination led to elevated TRAF5 expression and TRAF5‐mediated downstream NF‐κB/MAPK activation.Conclusion and Implications: Our study demonstrates that PRMT2 acts as a transcriptional co‐activator for proinflammatory genes during colitis. Hence, targeting PRMT2 may provide a novel therapeutic approach for colitis.Keywords
Funding Information
- National Natural Science Foundation of China (82122068, 80270666, 31900644, 81870439)
- Qinglan Project of Jiangsu Province of China
- Fundamental Research Funds for the Central Universities (JUSRP221037, JUSRP22007)
- Collaborative Innovationcenter of Food Safety and Quality Control in Jiangsu Province
This publication has 60 references indexed in Scilit:
- IL-10 Inhibits the NF-κB and ERK/MAPK-Mediated Production of Pro-Inflammatory Mediators by Up-Regulation of SOCS-3 in Trypanosoma cruzi-Infected CardiomyocytesPLOS ONE, 2013
- Protein arginine methyltransferases and cancerNature Reviews Cancer, 2012
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Disruption of Protein Arginine N -Methyltransferase 2 Regulates Leptin Signaling and Produces Leanness In Vivo Through Loss of STAT3 MethylationCirculation Research, 2010
- β-Catenin Primes Organizer Gene Expression by Recruiting a Histone H3 Arginine 8 Methyltransferase, Prmt2Developmental Cell, 2010
- Effective in vivo and ex vivogene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectorsBMC Gastroenterology, 2010
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Chemically induced mouse models of intestinal inflammationNature Protocols, 2007
- The arginine methyltransferase PRMT2 binds RB and regulates E2F functionExperimental Cell Research, 2006
- Protein Methyltransferase 2 Inhibits NF-κB Function and Promotes ApoptosisMolecular and Cellular Biology, 2006